Bubendorf, August 1, 2024 – CIS BIOPHARMA AG launches its new website. The team at CIS BIOPHARMA is excited to announce the launch of its new website, designed to connect with the global cancer research community. This new digital home is the result of a collaboration with admaxx, an upcoming creative agency based in Switzerland.

The website showcases our cutting-edge cancer therapies, including antibody-drug conjugates, ADCs, and radioligand therapies, and provides information about our pipeline and ongoing research.

Christoph Schäfer, CEO of CIS BIOPHARMA, shares his enthusiasm: «Our new webhome is a testament to our commitment to cancer research and to the extended collaboration in that field with leading institutes such as ETH Zurich. The webhome allows us to share our groundbreaking work with a wider audience and to engage with potential partners.“

Thomas Weilinger, Partner at admaxx says: «Working with CIS BIOPHARMA has been a rewarding experience. Their dedication to innovation and improving patient outcomes is truly inspiring, and we are proud to have created a new webhome that reflects their vision and mission.“

About CIS BIOPHARMA AG

CIS BIOPHARMA is a privately owned, Basel-based oncology company that develops next-generation immuno-conjugates to address aggressive forms of tumors. The product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs, selectively targeting tumor cells. CIS BIOPHARMA aims to help cancer patients live longer and better lives.